Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. peanut
Show results for
Products
Services
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Peanut Articles & Analysis

29 news found

Summer Allergies and Mitigating Exposure to Indoor Allergens and Respiratory Irritants

Summer Allergies and Mitigating Exposure to Indoor Allergens and Respiratory Irritants

“There’s an enormous number of potential allergens in the air and on surfaces from mold spores, to peanut dust, to cat dander and more. Allergen concentrations are highly variable by region, by season, and by conditions within the built environment. ...

ByCochrane & Associates, LLC


CD BioGlyco Now Provides Comprehensive Lectin Products for Glycobiology Research

CD BioGlyco Now Provides Comprehensive Lectin Products for Glycobiology Research

Commonly used is Phytoagglutin (PNA), which is usually named after the plant from which it is extracted, such as Conconvalina (ConA), Wheat germ agglutinin (WGA), Peanut agglutinin (Peanut agglutinin, PNA) and soybean lectin (Soybean agglutinin, SBA), etc., lectin is their general term. Featured Products Lectins X23-02-ZQ300 Agaricus bisporus lectin ...

ByCD BioGlyco.


Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy

Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy

Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology ...

ByIntrommune Therapeutics


Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy

Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy. ...

ByIntrommune Therapeutics


ANGANY Gaining Momentum for Plant-Based Immunotherapy Platform

ANGANY Gaining Momentum for Plant-Based Immunotherapy Platform

The initial two product candidates for human medicine are vaccines against cat allergy and peanut allergy, the first of which will enter clinical development in the second half of 2022. ...

ByAngany Inc.


Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory

Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory

NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Nandini Murthy as Head of Regulatory. ...

ByIntrommune Therapeutics


The Essential Guide to Food Allergies

The Essential Guide to Food Allergies

It is quite possible a healthy mother would have a child with peanut allergies. Even a very tiny piece of food that you are allergic to, can make health worse. ...

ByHYCOR Biomedical


FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis

FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis

In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including eosinophilic esophagitis (Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), chronic rhinosinusitis without nasal polyposis (Phase 3), chronic obstructive pulmonary disease with ...

ByRegeneron Pharmaceuticals Inc.


Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes including pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), chronic obstructive pulmonary disease with evidence of type 2 inflammation (Phase 3), eosinophilic esophagitis (Phase 3), bullous pemphigoid ...

ByRegeneron Pharmaceuticals Inc.


INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose

INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose

NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has been amended to allow ...

ByIntrommune Therapeutics


Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy

Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy

NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an initial update from its ongoing Phase 1 OMEGA Trial of INT301 in patients with peanut allergy. INT301 is a novel ...

ByIntrommune Therapeutics


Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships

Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships

NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the promotion of Sergi Trilla, MD to become Director of Corporate Strategy & Partnerships. ...

ByIntrommune Therapeutics


Angany and Lincoln Diagnostics to Collaborate on Angany’s Outreach to US Allergists

Angany and Lincoln Diagnostics to Collaborate on Angany’s Outreach to US Allergists

Angany’s first two therapeutic products will be used in the treatment of allergy to peanuts and human allergy to cats. The two companies will share a booth at the 2021 Annual Scientific Meeting of the American College of Asthma Allergy and Immunology (ACAAI) to be held from November 4th to 8th in New Orleans. ...

ByAngany Inc.


Intrommune Therapeutics Launches #PeanutAllergyStrong

Intrommune Therapeutics Launches #PeanutAllergyStrong

“Supporting peanut allergy patients and their loved ones has always been the central mission at Intrommune,” said Michael Nelson, CEO of Intrommune Therapeutics. ...

ByIntrommune Therapeutics


Alex Huybens appointed as Chief Executive Officer (CEO) of HAL Allergy Holding B.V. and HALIX B.V.

Alex Huybens appointed as Chief Executive Officer (CEO) of HAL Allergy Holding B.V. and HALIX B.V.

Through its pipeline portfolio (including AIT candidates for food, especially peanut, in clinical and preclinical stage), HAL Allergy is well-positioned to meet its growth ambitions and enhance the quality of life for millions of people. ...

ByHAL Allergy Group


Intrommune Therapeutics to Present at BIO Digital 2021

Intrommune Therapeutics to Present at BIO Digital 2021

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. ...

ByIntrommune Therapeutics


A cocktail of monoclonal antibodies produced in plants demonstrates high neutralizing potency to fight COVID-19 and variants

A cocktail of monoclonal antibodies produced in plants demonstrates high neutralizing potency to fight COVID-19 and variants

Angany is currently preparing a treatment for peanut allergy and products for human allergy to cats. ANGANY has also developed a flexible, fast and easily scalable 3rd generation plant-based production platform. ...

ByAngany Inc.


Medigen and BlueWillow Biologics Partner to Develop Intranasal Vaccine for SARS-CoV-2

Medigen and BlueWillow Biologics Partner to Develop Intranasal Vaccine for SARS-CoV-2

The adjuvant includes soybean oil, water and a cationic surfactant cetylpirdinium chloride (CPC) and is currently in use in the company’s clinical-stage anthrax and pandemic flu programs and National Institutes of Health (NIH)-funded preclinical stage RSV, HSV and peanut immunotherapy programs. When used with intranasal vaccination, the NE adjuvant elicits both mucosal and ...

ByBlueWillow Biologics


FDA Clears First Blood Test for Identifying a Novel Allergic Sensitization to Red Meat

FDA Clears First Blood Test for Identifying a Novel Allergic Sensitization to Red Meat

The tests can help identify allergic sensitization to common environmental allergens – seasonal and perennial, outdoor and indoor– as well as common food allergens such as peanut, egg and milk. The ImmunoCAP Specific IgE Stinging Insect Allergen Component tests were recently cleared by the FDA to help improve the diagnosis of bee and wasp allergies. ...

ByThermo Fisher Scientific, LIMS & Laboratory Software


New Blood Test Helps Clinicians Pinpoint A Potentially Life-Threatening Sensitization to Insect Stings

New Blood Test Helps Clinicians Pinpoint A Potentially Life-Threatening Sensitization to Insect Stings

The tests can identify allergic sensitization to common environmental allergens – seasonal and perennial, outdoor and indoor– as well as common food allergens such as peanut, egg and milk. The ImmunoCAP Specific IgE Pet Allergen Components were also recently cleared by the FDA and can help improve the diagnosis of dog, cat and horse allergies. ...

ByThermo Fisher Scientific, LIMS & Laboratory Software

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT